Lansoprazole-sulfide, pharmacokinetics of this promising anti-tuberculous agent.

Mdanda S, Baijnath S, Shobo A, Singh SD, Maguire GEM, Kruger HG, Arvidsson PI, Naicker T, Govender T

Biomed. Chromatogr. 31 (12) - [2017-12-00; online 2017-07-13]

Lansoprazole (LPZ) is a commercially available proton-pump inhibitor whose primary metabolite, lansoprazole sulfide (LPZS) was recently reported to have in vitro and in vivo activity against Mycobacterium tuberculosis. It was also reported that a 300 mg kg

Affiliated researcher

PubMed 28623874

DOI 10.1002/bmc.4035

Crossref 10.1002/bmc.4035

Publications 9.5.0